A REGISTRY-BASED CASE-CONTROL STUDY Guri Hagberg 1,2 , Hkon Ihle-Hansen 3,4 , Tamar Abzhandadze 2,5 , Malin Reinholdsson 2,5 , Adam Viktorisson 2,6 , Henri Pesonen 7 , Hege Ihle-Hansen 4 , Katharina Stibrant Sunnerhagen 2,6 1 Oslo Stroke Unit, Department of Neurology, Oslo University Hospital, Oslo, Norway, 2 Institute of Neuroscience and Physiology, Section for Clinical Neuroscience and Rehabilitation, Gothenburg University, Gothenburg, Sweden, 3 Department of Medicine, Brum Hospital- Vestre Viken Hospital Trust, Drammen, Norway, 4 Research department Brum Hospital, Vestre Viken Hospital Trust, Drammen, Norway, 5 Department of Occupational Therapy and Physiotherapy, Sahlgrenska University Hospital, Gothenborg, Sweden, 6 Neurocare, Sahlgrenska University Hospital, Gothenburg, Sweden, 7 Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway Background and Aims: Patient reported outcome measures (PROMs) could expose meaningful differences but are scarcely investigated in acute stroke trials

TB-500 is a synthetic version of a fragment of Thymosin Beta-4, a protein present at high concentrations throughout human tissue that plays a central role in cell migration, angiogenesis, and the regulation of inflammation
The rate at which Fragment 176-191 caused AEs was not statistically different from the rate at which placebos caused AEs
Varicella-zoster virus in the saliva of patients with herpes zoster
The NNMT-NAD+-Sirtuin Axis: How 5-Amino-1MQ Connects to Longevity Research The most scientifically compelling aspect of this compound is its mechanistic connection to the NAD+-sirtuin axis the same pathway that drives the enormous research interest in NAD+ supplementation, NMN, and NR